Eli Lilly Pauses Enrollment in ACTIV-3 Clinical Trial Due to Safety Concerns,

The independent DSMB recommended pausing the enrollment of the ACTIV-3 clinical trial. The trial is evaluating Lilly’s bamlanivimab (LY-CoV555, …, The independent DSMB recommended pausing the enrollment of the ACTIV-3 clinical trial. The trial is evaluating Lilly’s bamlanivimab (LY-CoV555, …, Read More

Scroll to Top